Laureate Pharma, Inc. has entered into a biopharmaceutical manufacturing agreement with Iconic Therapeutics, Inc. for cGMP manufacture of hI-con1, a “bi-functional immunoprotein.” Laureate’s services include cGMP protein production, purification and aseptic filling of hI-con1 for Iconic Therapeutics. Terms of the agreement were not disclosed. “Iconic Therapeutics has a unique bi-functional immunoprotein for the treatment of wet adult macular degeneration and cancer a...